Human Rabies Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Vaccine Type (Killed Rabies Vaccines, Rabies Immunoglobulins, Rabies Monoclonal Antibodies), By Route of Administration (Intra Muscular, Intra Dermal), By Product Type (Chicken Embryo Cell Vaccines, Vero Cells, Human Diploid Cell Vaccines), By Application (Pre-exposure Prophylaxis(Pr-EP), Post-exposure Prophylaxis (PEP)) and Region

Human Rabies Vaccine Market size was valued at US$ 1,343.6 million in 2023 and is estimated to grow at 4.9% CAGR from 2024 to 2030. Human Rabies vaccine is the class of vaccines that gives protection from a zoonotic disease called rabies mainly spread by dogs. There are three types of vaccines specifically chicken embryo cell vaccines (CCEEV), Vero cells, and Human diploid cell vaccines. The market of Human Rabies Vaccine includes killed rabies vaccines, rabies immunoglobulins, and monoclonal antibodies and recent trends are of DNA and mRNA vaccines. The key drivers of the Human Rabies Vaccine are the urbanization of stray dogs, government and various healthcare organizations initiatives, increased pet ownership, and increasing awareness about vaccines.

The opportunities for the companies for the market are the increased awareness and vaccination initiatives of certain organizations such National Rabies Control Program (NRCP) from the Indian government, the Thailand Red Cross (TRC), etc. The key trends in the market are the increasing occurrence of rabies, and presence of key players in vaccine manufacturing, and the availability of vaccines in rural areas. As per WHO, the suggestion of switching to ID (Intra-Dermal) form IM (Intra-Muscular) based administration will help reduce the Human Rabies Vaccine usage from the current scenario of 60M vials to 20M vials per year globally (driven by China). This happens because the dosage regime is significantly reduced from 0.5 - 1 ml to 0.1 ml from IM to ID respectively. The market is also affected by the WHO program of increasing oral vaccination of wild and tame animals. Despite the decrease in vaccine usage, because of the “ZERO by 30” program from WHO the global market is expected to expand. The major producers and end users of the Human Rabies Vaccine in the global market are China and India.

Rabies is a deadly viral disease transmitted primarily through animal bites. Human rabies vaccines play a crucial role in preventing rabies infection and saving lives. Travel advisories and educational programs targeted towards travelers visiting rabies-endemic regions create a growing market for PrEP vaccines to ensure travelers are adequately protected. Also, community outreach programs in high-risk areas educate people about rabies prevention measures, including responsible pet ownership and the importance of post-exposure prophylaxis (PEP) after animal bites. This awareness fuels demand for PEP vaccines. Moreover, the "Zero by 30" initiative spearheaded by the World Health Organization (WHO) aims to eliminate dog-mediated human rabies deaths by 2030. This global focus translates to increased funding and support for rabies control programs, leading to a rise in vaccine demand. Many countries are implementing mass vaccination campaigns for dogs, the primary reservoir of rabies.

This indirect strategy reduces the risk of rabies transmission to humans and creates a smaller, long-term demand for PEP vaccines. Also, investments in healthcare infrastructure, particularly in developing regions, improve access to rabies vaccines and post-exposure treatment, driving market growth. A growing global middle class with increased disposable income is leading to more people traveling internationally, often to areas with higher rabies prevalence. This necessitates PrEP for travelers, boosting market demand. Increased global trade and movement of animals can inadvertently introduce rabies strains into new regions. This underscores the importance of rabies control programs and vaccination efforts. Additionally, the growing trend towards responsible pet ownership and animal welfare initiatives can lead to increased pet vaccinations, indirectly impacting the human rabies vaccines market by reducing the risk of rabies transmission from animals to humans. However, uneven access to healthcare facilities and robust cold chain infrastructure in some regions can hinder vaccine distribution and administration.

Human Rabies Vaccine Market Key Developments:

• In April 2024. Sanofi has announced the launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK, an inactivated rabies vaccine indicated for pre-exposure and post-exposure rabies prophylaxis in all age groups.
• In July 2024, Gavi, the Vaccine Alliance, in collaboration with partners, is announcing support for human rabies vaccines for post-exposure prophylaxis (PEP) as part of routine immunization. Eligible countries are receiving guidance on how to access these vaccines under Gavi's cofinancing policy. The first round of applications will be accepted by mid-July 2024
• In December 2022, Everest Medicines launched a novel mRNA Rabies Vaccine development and the completion of a preclinical proof-of-concept study. This is a association with Providence Therapeutics that concentrates on a new rabies vaccine candidate.
• In April 2022, Cadila Pharmaceuticals released a three-dose recombinant nanoparticle-based G protein rabies vaccine in Ahmedabad. This regimen is to be given over one week (on day 0, day three, and day seven) after exposure to the virus. It is the first in a long list of existing rabies vaccines that require five doses.